The Cancer Protocol Industry Giants Hope You Never Find
Anyone who has watched a family member go through cancer knows the ugly truth about standard oncology
You get shoved onto an aggressive, wildly expensive conveyor belt of murderous treatments that ravage the human body, poison healthy tissue, and line the pockets of corporate cartels.
If a therapy does not generate billions under an exclusive patent, the medical establishment simply has no use for it.
That is why the report Dr. Peter McCullough is highlighting matters so much, and why the gatekeepers want it buried.
A recent observational study followed 197 cancer patients who added two common, off-patent drugs to their care: compounded ivermectin and mebendazole.
The outcomes are staggering. Over 84 percent experienced measurable clinical benefit, with nearly half seeing actual tumor reduction or no remaining sign of disease.
Side effects were minimal, and these generic compounds cost pennies compared to the brutal regimens being pushed in hospital wards every day.
For anyone that has cancer this is important information that Dr. Peter McCullough is discussing.
A recent observational report looked at 197 cancer patients prescribed compounded ivermectin (25 mg) plus mebendazole (250 mg). After six months, 122 patients completed follow-up surveys.
Here’s what those surveys showed:
84.4 percent reported clinical benefit (no evidence of disease, tumor regression, or stable disease)
48.4 percent reported tumor reduction or no detectable disease
36.1 percent reported stable disease
15.6 percent reported progression
86.9 percent completed the initial treatment course
Side effects were mostly mild (mainly gastrointestinal) and reported by about 25 percent of patients.
Many patients were also receiving other treatments at the same time, including chemotherapy, radiation, surgery, supplements, and diet changes.
Prostate and breast cancer were the most common diagnoses in the group.
The rest of this article is behind a paywall. See it here substack.com
Header image: Mark Kostich